{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T02:13:57Z","timestamp":1772849637648,"version":"3.50.1"},"reference-count":45,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","award":["W81XWH-15-1-0097"],"award-info":[{"award-number":["W81XWH-15-1-0097"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["international-journal-of-gynecological-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Gynecological Cancer"],"published-print":{"date-parts":[[2019,8]]},"DOI":"10.1136\/ijgc-2019-000490","type":"journal-article","created":{"date-parts":[[2019,8,28]],"date-time":"2019-08-28T14:55:16Z","timestamp":1567004116000},"page":"s7-s11","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"S2","title":["Genomics and molecular mechanisms of high grade serous ovarian cancer: the 12th Biennial Rivkin Center Ovarian Cancer Research Symposium"],"prefix":"10.1016","volume":"29","author":[{"given":"Erinn B","family":"Rankin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1136\/ijgc-2019-000490_bb0010","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1038\/nrc4019","article-title":"Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer","volume":"15","author":"Bowtell","year":"2015","journal-title":"Nat Rev Cancer"},{"key":"10.1136\/ijgc-2019-000490_bb0015","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/S1470-2045(06)70939-1","article-title":"Mechanisms of transcoelomic metastasis in ovarian cancer","volume":"7","author":"Tan","year":"2006","journal-title":"Lancet Oncol"},{"key":"10.1136\/ijgc-2019-000490_bb0020","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1038\/nature10166","article-title":"Integrated genomic analyses of ovarian carcinoma","volume":"474","author":"Cancer Genome Atlas Research Network","year":"2011","journal-title":"Nature"},{"key":"10.1136\/ijgc-2019-000490_bb0025","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1038\/ng.2762","article-title":"Emerging landscape of oncogenic signatures across human cancers","volume":"45","author":"Ciriello","year":"2013","journal-title":"Nat Genet"},{"key":"10.1136\/ijgc-2019-000490_bb0030","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.ceb.2017.11.005","article-title":"Deciphering p53 signaling in tumor suppression","volume":"51","author":"Mello","year":"2018","journal-title":"Curr Opin Cell Biol"},{"key":"10.1136\/ijgc-2019-000490_bb0035","doi-asserted-by":"crossref","DOI":"10.3390\/cancers10120468","article-title":"Back to the future? The fallopian tube, Precursor escape and a dualistic model of high-grade serous carcinogenesis","volume":"10","author":"Soong","year":"2018","journal-title":"Cancers"},{"key":"10.1136\/ijgc-2019-000490_bb0040","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1002\/path.4927","article-title":"High-grade serous carcinomas arise in the mouse oviduct via defects linked to the human disease","volume":"243","author":"Zhai","year":"2017","journal-title":"J Pathol"},{"key":"10.1136\/ijgc-2019-000490_bb0045","first-page":"40","article-title":"Is \"ovarian\" cancer a misnomer? Exploring ovarian cancer origins in the mouse","volume":"129","author":"Cho","year":"2018","journal-title":"Trans Am Clin Climatol Assoc"},{"key":"10.1136\/ijgc-2019-000490_bb0050","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1038\/s41591-019-0422-6","article-title":"An organoid platform for ovarian cancer captures intra- and interpatient heterogeneity","volume":"25","author":"Kopper","year":"2019","journal-title":"Nat Med"},{"key":"10.1136\/ijgc-2019-000490_bb0055","doi-asserted-by":"crossref","first-page":"28152","DOI":"10.1074\/jbc.M112.340638","article-title":"Mutant p53 aggregates into prion-like amyloid oligomers and fibrils: implications for cancer","volume":"287","author":"Ano Bom","year":"2012","journal-title":"J Biol Chem"},{"key":"10.1136\/ijgc-2019-000490_bb0060","doi-asserted-by":"crossref","first-page":"13273","DOI":"10.1021\/acs.analchem.8b02373","article-title":"Polymer-ligand-based ELISA for robust, high-throughput, quantitative detection of p53 aggregates","volume":"90","author":"Maritschnegg","year":"2018","journal-title":"Anal Chem"},{"key":"10.1136\/ijgc-2019-000490_bb0065","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1158\/1535-7163.MCT-12-0712","article-title":"FOX(M1) news--it is cancer","volume":"12","author":"Halasi","year":"2013","journal-title":"Mol Cancer Ther"},{"key":"10.1136\/ijgc-2019-000490_bb0070","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1038\/ncb1217","article-title":"FoxM1 is required for execution of the mitotic programme and chromosome stability","volume":"7","author":"Laoukili","year":"2005","journal-title":"Nat Cell Biol"},{"key":"10.1136\/ijgc-2019-000490_bb0075","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0023790","article-title":"Aberrant activation of ERK\/FOXM1 signaling cascade triggers the cell migration\/invasion in ovarian cancer cells","volume":"6","author":"Lok","year":"2011","journal-title":"PLoS One"},{"key":"10.1136\/ijgc-2019-000490_bb0080","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.18632\/oncotarget.2957","article-title":"FOXM1 confers to epithelial-mesenchymal transition, stemness and chemoresistance in epithelial ovarian carcinoma cells","volume":"6","author":"Chiu","year":"2015","journal-title":"Oncotarget"},{"key":"10.1136\/ijgc-2019-000490_bb0085","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1158\/1541-7786.MCR-17-0607","article-title":"Olaparib-induced adaptive response is disrupted by FOXM1 targeting that enhances sensitivity to PARP inhibition","volume":"16","author":"Fang","year":"2018","journal-title":"Mol Cancer Res"},{"key":"10.1136\/ijgc-2019-000490_bb0090","doi-asserted-by":"crossref","first-page":"4295","DOI":"10.1038\/onc.2009.282","article-title":"Pro-proliferative FoxM1 is a target of p53-mediated repression","volume":"28","author":"Barsotti","year":"2009","journal-title":"Oncogene"},{"key":"10.1136\/ijgc-2019-000490_bb0095","doi-asserted-by":"crossref","first-page":"27613","DOI":"10.18632\/oncotarget.4546","article-title":"Genetic determinants of FOXM1 overexpression in epithelial ovarian cancer and functional contribution to cell cycle progression","volume":"6","author":"Barger","year":"2015","journal-title":"Oncotarget"},{"key":"10.1136\/ijgc-2019-000490_bb0100","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1093\/emboj\/17.2.598","article-title":"Rad51-deficient vertebrate cells accumulate chromosomal breaks prior to cell death","volume":"17","author":"Sonoda","year":"1998","journal-title":"Embo J"},{"key":"10.1136\/ijgc-2019-000490_bb0105","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1038\/nature03445","article-title":"Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy","volume":"434","author":"Farmer","year":"2005","journal-title":"Nature"},{"key":"10.1136\/ijgc-2019-000490_bb0110","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1001\/jama.2011.1456","article-title":"Association of BRCA1 and BRCA2 mutations with survival, chemotherapy sensitivity, and gene mutator phenotype in patients with ovarian cancer","volume":"306","author":"Yang","year":"2011","journal-title":"JAMA"},{"key":"10.1136\/ijgc-2019-000490_bb0115","doi-asserted-by":"crossref","first-page":"4257","DOI":"10.1158\/1078-0432.CCR-15-0887","article-title":"FDA approval summary: olaparib monotherapy in patients with deleterious germline BRCA-mutated advanced ovarian cancer treated with three or more lines of chemotherapy","volume":"21","author":"Kim","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1136\/ijgc-2019-000490_bb0120","doi-asserted-by":"crossref","first-page":"7165","DOI":"10.1158\/1078-0432.CCR-17-1337","article-title":"FDA approval summary: rucaparib for the treatment of patients with deleterious BRCA mutation-associated advanced ovarian cancer","volume":"23","author":"Balasubramaniam","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1136\/ijgc-2019-000490_bb0125","doi-asserted-by":"crossref","first-page":"4066","DOI":"10.1158\/1078-0432.CCR-18-0042","article-title":"FDA approval summary: niraparib for the maintenance treatment of patients with recurrent ovarian cancer in response to platinum-based chemotherapy","volume":"24","author":"Ison","year":"2018","journal-title":"Clin Cancer Res"},{"key":"10.1136\/ijgc-2019-000490_bb0130","doi-asserted-by":"crossref","first-page":"e15","DOI":"10.1016\/S1470-2045(18)30786-1","article-title":"Exploring and comparing adverse events between PARP inhibitors","volume":"20","author":"LaFargue","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1136\/ijgc-2019-000490_bb0135","doi-asserted-by":"crossref","DOI":"10.1158\/1078-0432.CCR-19-0619","article-title":"Advancing drug development in gynecologic malignancies","author":"Beaver","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1136\/ijgc-2019-000490_bb0140","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/S1470-2045(14)71135-0","article-title":"Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial","volume":"16","author":"Oza","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1136\/ijgc-2019-000490_bb0145","doi-asserted-by":"crossref","first-page":"5626","DOI":"10.1158\/0008-5472.CAN-11-1227","article-title":"Phase I study of PARP inhibitor ABT-888 in combination with topotecan in adults with refractory solid tumors and lymphomas","volume":"71","author":"Kummar","year":"2011","journal-title":"Cancer Res"},{"key":"10.1136\/ijgc-2019-000490_bb0150","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.1158\/1078-0432.CCR-11-2425","article-title":"A phase I combination study of olaparib with cisplatin and gemcitabine in adults with solid tumors","volume":"18","author":"Rajan","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1136\/ijgc-2019-000490_bb0155","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1158\/2159-8290.CD-18-0474","article-title":"Prediction of DNA repair inhibitor response in short-term patient-derived ovarian cancer organoids","volume":"8","author":"Hill","year":"2018","journal-title":"Cancer Discov"},{"key":"10.1136\/ijgc-2019-000490_bb0160","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1038\/nature03443","article-title":"Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase","volume":"434","author":"Bryant","year":"2005","journal-title":"Nature"},{"key":"10.1136\/ijgc-2019-000490_bb0165","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1158\/2159-8290.CD-15-0714","article-title":"Homologous recombination deficiency: exploiting the fundamental vulnerability of ovarian cancer","volume":"5","author":"Konstantinopoulos","year":"2015","journal-title":"Cancer Discov"},{"key":"10.1136\/ijgc-2019-000490_bb0170","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1158\/1541-7786.MCR-09-0299","article-title":"Acquired resistance to combination treatment with temozolomide and ABT-888 is mediated by both base excision repair and homologous recombination DNA repair pathways","volume":"7","author":"Liu","year":"2009","journal-title":"Mol Cancer Res"},{"key":"10.1136\/ijgc-2019-000490_bb0175","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-018-03917-2","article-title":"Genome-wide and high-density CRISPR-Cas9 screens identify point mutations in PARP1 causing PARP inhibitor resistance","volume":"9","author":"Pettitt","year":"2018","journal-title":"Nat Commun"},{"key":"10.1136\/ijgc-2019-000490_bb0180","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1038\/nature14328","article-title":"REV7 counteracts DNA double-strand break resection and affects PARP inhibition","volume":"521","author":"Xu","year":"2015","journal-title":"Nature"},{"key":"10.1136\/ijgc-2019-000490_bb0185","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.cell.2010.03.012","article-title":"53BP1 inhibits homologous recombination in Brca1-deficient cells by blocking resection of DNA breaks","volume":"141","author":"Bunting","year":"2010","journal-title":"Cell"},{"key":"10.1136\/ijgc-2019-000490_bb0190","doi-asserted-by":"crossref","first-page":"3529","DOI":"10.1242\/jcs.105353","article-title":"BRCA1-associated exclusion of 53BP1 from DNA damage sites underlies temporal control of DNA repair","volume":"125","author":"Chapman","year":"2012","journal-title":"J Cell Sci"},{"key":"10.1136\/ijgc-2019-000490_bb0195","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1038\/nsmb.3236","article-title":"Human BRCA1-BARD1 ubiquitin ligase activity counteracts chromatin barriers to DNA resection","volume":"23","author":"Densham","year":"2016","journal-title":"Nat Struct Mol Biol"},{"key":"10.1136\/ijgc-2019-000490_bb0200","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1038\/nsmb.1831","article-title":"53BP1 loss rescues BRCA1 deficiency and is associated with triple-negative and BRCA-mutated breast cancers","volume":"17","author":"Bouwman","year":"2010","journal-title":"Nat Struct Mol Biol"},{"key":"10.1136\/ijgc-2019-000490_bb0205","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1158\/2159-8290.CD-12-0049","article-title":"Loss of 53BP1 causes PARP inhibitor resistance in Brca1-mutated mouse mammary tumors","volume":"3","author":"Jaspers","year":"2013","journal-title":"Cancer Discov"},{"key":"10.1136\/ijgc-2019-000490_bb0210","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1016\/j.cell.2018.03.050","article-title":"DNA repair network analysis reveals shieldin as a key regulator of NHEJ and PARP inhibitor sensitivity","volume":"173","author":"Gupta","year":"2018","journal-title":"Cell"},{"key":"10.1136\/ijgc-2019-000490_bb0215","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1038\/s41586-018-0670-5","article-title":"DYNLL1 binds to MRE11 to limit DNA end resection in BRCA1-deficient cells","volume":"563","author":"He","year":"2018","journal-title":"Nature"},{"key":"10.1136\/ijgc-2019-000490_bb0220","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-018-07855-x","article-title":"The ASCIZ-DYNLL1 axis promotes 53BP1-dependent non-homologous end joining and PARP inhibitor sensitivity","volume":"9","author":"Becker","year":"2018","journal-title":"Nat Commun"},{"key":"10.1136\/ijgc-2019-000490_bb0225","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1038\/s41588-018-0179-8","article-title":"Copy number signatures and mutational processes in ovarian carcinoma","volume":"50","author":"Macintyre","year":"2018","journal-title":"Nat Genet"},{"key":"10.1136\/ijgc-2019-000490_bb0230","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1038\/ng.3826","article-title":"Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer","volume":"49","author":"Phelan","year":"2017","journal-title":"Nat Genet"}],"container-title":["International Journal of Gynecological Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X24011587?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X24011587?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ijgc-2019-000490","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T01:23:46Z","timestamp":1753233826000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1048891X24011587"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8]]},"references-count":45,"alternative-id":["S1048891X24011587"],"URL":"https:\/\/doi.org\/10.1136\/ijgc-2019-000490","relation":{},"ISSN":["1048-891X"],"issn-type":[{"value":"1048-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2019,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Genomics and molecular mechanisms of high grade serous ovarian cancer: the 12th Biennial Rivkin Center Ovarian Cancer Research Symposium","name":"articletitle","label":"Article Title"},{"value":"International Journal of Gynecological Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/ijgc-2019-000490","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2019 This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, an indication of whether changes were made, and the use is non-commercial. See: http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/.","name":"copyright","label":"Copyright"}]}}